31 | 296: Legal insider trading, booming biotech stocks, & the next GLP-1 2024-02-29 |
Play |
32 | 295: Humira’s legacy, CEO symbolism, and genomic surgery 2024-02-22 |
Play |
33 | 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking 2024-02-15 |
Play |
34 | 293: AI in medicine, detangling hype, and Icelandic DNA 2024-02-08 |
Play |
35 | 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon 2024-02-01 |
Play |
36 | 291: The plight of the VC, Gilead's latest setback, & more M&A 2024-01-25 |
Play |
37 | 290: Biotech layoffs, slumping stocks, and a 2024 preview 2024-01-18 |
Play |
38 | 289: Live! From #JPM24 2024-01-11 |
Play |
39 | 287: 2023 in review, CEO report cards, and a look at the year ahead 2023-12-21 |
Play |
40 | 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future 2023-12-14 |
Play |